New perspectives on the neuropathology in Huntington's disease in the human brain and its relation to symptom variation

Journal of Huntington's Disease

Volumn 1, Issue 2, 2012, Pages 143-153

  Waldvogel, Henry J ^a   Kim, Eric H ^a   Thu, Doris C V ^b   Tippett, Lynette J ^a   Faull, Richard L M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b EPFL   (Switzerland)

Author keywords

basal ganglia; cortex; human brain; Huntington's disease; pathology; symptoms

Indexed keywords

HUNTINGTIN; NEUROTENSIN; NERVE PROTEIN;

AUTOPSY; BASAL GANGLION; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN CORTEX; BRAIN SIZE; BRAIN WEIGHT; CAG REPEAT; CLINICAL FEATURE; COGNITIVE DEFECT; CORPUS STRIATUM; DISEASE COURSE; EXON; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPATHOLOGY; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVIEW; ANIMAL; ATROPHY; BIOLOGICAL MODEL; BRAIN; HUNTINGTON DISEASE; METABOLISM; PATHOLOGY; SYMPTOM ASSESSMENT;

ANIMALS; ATROPHY; BRAIN; HUMANS; HUNTINGTON DISEASE; MODELS, NEUROLOGICAL; NERVE TISSUE PROTEINS; SYMPTOM ASSESSMENT;

EID: 84924914420     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-2012-120018     Document Type: Review

References (135)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-83.
2. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nature genetics. 1993;4(4):393-7. (Pubitemid 23231489)
3. Nance MA. Clinical aspects of CAG repeat diseases. Brain Pathology. 1997;7(3):881-900. (Pubitemid 27346733)
4. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Annals of Neurology. 1997;41(5):689-92. (Pubitemid 27212666)
5. Andresen JM, Gayan J, Djousse L, Roberts S, Brocklebank D, Cherny SS, et al. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Annals of Human Genetics. 2007;71(Pt 3):295-301. (Pubitemid 46585671)
6. Andrew SE, Goldberg YP, Kremer B,Telenius H, Theilmann J, Adam S, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nature genetics. 1993;4(4):398-403. (Pubitemid 23231490)
7. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nature genetics. 1993;4(4):387-92. (Pubitemid 23231488)
8. Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mechanisms of ageing and development. 2006; 127(2):208-12. (Pubitemid 43165620)
9. Vonsattel JP, DiFiglia M. Huntington disease. Journal of neuropathology and experimental neurology. 1998; 57(5):369-84. (Pubitemid 28237321)
10. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci. 2006;24(4):961-7. (Pubitemid 44268127)
11. Nance MA. Huntington disease: clinical, genetic, and social aspects. Journal of Geriatric Psychiatry and Neurology. 1998;11(2):61-70. (Pubitemid 29010210)
12. Thu DCV, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, et al. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain: A Journal of Neurology. 2010;133(Pt 4):1094-110.
13. Tippett LJ, Waldvogel HJ, Thomas SJ, Hogg VM, van Roon-Mom W, Synek BJ, et al. Striosomes and mood dysfunction in Huntington's disease. Brain: A Journal of Neurology. 2007;130(Pt 1):206-21. (Pubitemid 46026236)
14. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology. 2002;58(5):695-701. (Pubitemid 34211546)
15. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain: A Journal of Neurology. 2008;131(Pt 4):1057-68. (Pubitemid 351499426)
16. Walker FO. Huntington's disease. Lancet. 2007;369(9557): 218-28. (Pubitemid 46107685)
17. Huntington G. On chorea. Med Surg Reporter. 1872;26:317-21.
18. Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology. 1986;36(2):244-9. (Pubitemid 16124216)
19. Mahant N, McCusker EA, Byth K, Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003;61(8):1085-92. (Pubitemid 37461942)
20. Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G, et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord. 1999; 14(3):398-403. (Pubitemid 30011648)
21. Snowden JS, Craufurd D, Thompson J, Neary D. Psychomotor, executive, and memory function in preclinical Huntington's disease. J Clin Exp Neuropsychol. 2002;24(2):133-45. (Pubitemid 34496862)
22. Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ane MN, et al. Profile of cognitive progression in early Huntington's disease. Neurology. 2003;61(12):1702-06. (Pubitemid 38020815)
23. Montoya A, Price BH, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci. 2006;31(1):21-9.
24. Kirkwood SC, Su JL, Conneally P, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol. 2001;58(2):273-8. (Pubitemid 32163165)
25. Lawrence AD, Watkins LH, Sahakian BJ, Hodges JR, Robbins TW. Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits. Brain:AJournal of Neurology. 2000;123(Pt 7):1349-64. (Pubitemid 30420936)
26. Thompson JC, Snowden JS, Craufurd D, Neary D. Behavior in Huntington's disease: Dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci. 2002;14(1):37-43. (Pubitemid 34117021)
27. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71(3):310-4. (Pubitemid 32772526)
28. Rosenblatt A, Leroi I. Neuropsychiatry of Huntington's disease and other basal ganglia disorders. Psychosomatics. 2000;41(1):24-30. (Pubitemid 30062894)
29. Anderson KE, Louis ED, Stern Y, Marder KS. Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease. Am J Psychiatry. 2001;158(5):799-801. (Pubitemid 32429851)
30. Cummings JL, Cunningham K. Obsessive-compulsive disorder in Huntington's disease. Biol Psychiatry. 1992;31(3):263-70.
31. Baliko L, Csala B, Czopf J. Suicide in Hungarian Huntington's disease patients. Neuroepidemiology. 2004;23(5): 258-60. (Pubitemid 39179157)
32. Robins Wahlin TB, Backman L, Lundin A, Haegermark A, Winblad B, Anvret M. High suicidal ideation in persons testing for Huntington's disease. Acta Neurol Scand. 2000;102(3):150-61. (Pubitemid 30648831)
33. Georgiou N, Bradshaw JL, Chiu E, Tudor A, O'Gorman L, Phillips JG. Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Mov Disord. 1999;14(2):320-5. (Pubitemid 30011851)
34. Anca MH, Gazit E, Loewenthal R, Ostrovsky O, Frydman M, Giladi N. Different phenotypic expression in monozygotic twins with Huntington disease. Am J Med Genet A. 2004;124A(1):89-91. (Pubitemid 38139822)
35. Gomez-Esteban JC, Lezcano E, Zarranz JJ, Velasco F, Garamendi I, Perez T, et al. Monozygotic twins suffering from Huntington's disease show different cognitive and behavioural symptoms. Eur Neurol. 2007;57(1):26-30. (Pubitemid 46143863)
36. Friedman JH, Trieschmann ME, Myers RH, Fernandez HH. Monozygotic twins discordant for Huntington disease after 7 years. Arch Neurol. 2005;62(6):995-7. (Pubitemid 40973463)
37. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(10):3498-503. (Pubitemid 38338224)
38. Meynert T. Discussion to Fritsch. 1877;4:47.
39. Aziz NA, Pijl H, Frolich M, van der Graaf AW, Roelfsema F, Roos RA. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. The Journal of Clinical Endocrinology and Metabolism. 2009;94(4):1223-8.
40. Vonsattel JP, Keller C, Del Pilar Amaya M. Neuropathology of Huntington's disease. Handb Clin Neurol. 2008;89:599-618.
41. de la Monte SM,Vonsattel JP, Richardson EP Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. Journal of Neuropathology and Experimental Neurology. 1988;47(5):516-25.
42. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. Journal of Neuropathology and Experimental Neurology. 1985;44(6):559-77. (Pubitemid 16196286)
43. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 1988;85(15):5733-37.
44. Albin RL, Reiner A, Anderson KD, Dure LSt, Handelin B, Balfour R, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Annals of Neurology. 1992;31(4):425-30.
45. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250(4986):1429-32. (Pubitemid 120031867)
46. Graybiel AM, Ragsdale CW Jr. Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proceedings of the National Academy of Sciences of the United States of America. 1978;75(11):5723-6. (Pubitemid 9101467)
47. Goedert M, Mantyh PW, Emson PC, Hunt SP. Inverse relationship between neurotensin receptors and neurotensinlike immunoreactivity in cat striatum. Nature. 1984; 307(5951):543-6. (Pubitemid 14135814)
48. Cote PY, Levitt P, Parent A. Distribution of limbic systemassociated membrane protein immunoreactivity in primate basal ganglia. Neuroscience. 1995;69(1):71-81.
49. Joyce JN, Sapp DW, Marshall JF. Human striatal dopamine receptors are organized in compartments. Proceedings of the National Academy of Sciences of the United States of America. 1986;83(20):8002-6. (Pubitemid 17183973)
50. Faull RL,Waldvogel HJ, Nicholson LF, Synek BJ. The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acidlesioned rat. Prog Brain Res. 1993;99:105-23. (Pubitemid 24015889)
51. Dure LSt, Young AB, Penney JB. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Annals of neurology. 1991;30(6):785-93.
52. Waldvogel HJ, Billinton A, White JH, Emson PC, Faull RL. Comparative cellular distribution of GABAA and GABAB receptors in the human basal ganglia: immunohistochemical colocalization of the alpha 1 subunit of the GABAA receptor, and the GABABR1 and GABABR2 receptor subunits. The Journal of comparative neurology. 2004;470(4): 339-56. (Pubitemid 38240937)
53. Waldvogel HJ, Kubota Y, Fritschy J, Mohler H, Faull RL. Regional and cellular localisation of GABA(A) receptor subunits in the human basal ganglia: An autoradiographic and immunohistochemical study. The Journal of comparative neurology. 1999;415(3):313-40.
54. Holt DJ, Graybiel AM, Saper CB. Neurochemical architecture of the human striatum. The Journal of comparative neurology. 1997;384(1):1-25. (Pubitemid 27280221)
55. Holt DJ, Hersh LB, Saper CB. Cholinergic innervation in the human striatum: a three-compartment model. Neuroscience. 1996;74(1):67-87. (Pubitemid 26291149)
56. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends in neurosciences. 1990;13(7):244-54. (Pubitemid 20193453)
57. Prensa L, Gimenez-Amaya JM, Parent A. Chemical heterogeneity of the striosomal compartment in the human striatum. The Journal of comparative neurology. 1999;413(4):603-18. (Pubitemid 29463632)
58. Voorn P, Gerfen CR, Groenewegen HJ. Compartmental organization of the ventral striatum of the rat: immunohistochemical distribution of enkephalin, substance P, dopamine, and calcium-binding protein. The Journal of comparative neurology. 1989;289(2):189-201. (Pubitemid 19270583)
59. Parent A, Fortin M, Cote PY, Cicchetti F. Calcium-binding proteins in primate basal ganglia. Neuroscience research. 1996;25(4):309-34. (Pubitemid 26270785)
60. Manley MS, Young SJ, Groves PM. Compartmental organization of the peptide network in the human caudate nucleus. Journal of chemical neuroanatomy. 1994;7(3):191-201. (Pubitemid 24310338)
61. Waldvogel HJ, Faull RL. Compartmentalization of parvalbumin immunoreactivity in the human striatum. Brain research. 1993;610(2):311-16. (Pubitemid 23154805)
62. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. Journal of neuropathology and experimental neurology. 1995;54(1):105-20.
63. Morton AJ, Nicholson LF, Faull RL. Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington's disease. Neuroscience. 1993;53(1):159-68. (Pubitemid 23083317)
64. Augood SJ, Faull RL, Love DR, Emson PC. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience. 1996;72(4):1023-36. (Pubitemid 26135583)
65. Seto-Ohshima A, Emson PC, Lawson E, Mountjoy CQ, Carrasco LH. Loss of matrix calcium-binding proteincontaining neurons in Huntington's disease. Lancet. 1988;1(8597):1252-5.
66. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP Jr. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. Journal of neuropathology and experimental neurology. 1987;46(1):12-27. (Pubitemid 17232251)
67. Gerfen CR. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature. 1984;311(5985):461-4. (Pubitemid 14035451)
68. Tokuno H, Chiken S, Kametani K, Moriizumi T. Efferent projections from the striatal patch compartment: anterograde degeneration after selective ablation of neurons expressing mu-opioid receptor in rats. Neurosci Lett. 2002;332(1):5-8.
69. Fujiyama F, Sohn J, Nakano T, Furuta T, Nakamura KC, Matsuda W, et al. Exclusive and common targets of neostriatofugal projections of rat striosome neurons: a single neuron-tracing study using a viral vector. Eur J Neurosci. 2011;33(4):668-77.
70. Parent A, Cote PY, Lavoie B. Chemical anatomy of primate basal ganglia. Progress in neurobiology. 1995;46(2-3):131-97.
71. Cudkowicz M, KowallNW. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Annals of neurology. 1990;27(2):200-4. (Pubitemid 20086642)
72. Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett. 1991;133(2):257-61.
73. Heinsen H, Strik M, Bauer M, Luther K, Ulmar G, Gangnus D, et al. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol (Berl). 1994;88(4):320-33. (Pubitemid 24309396)
74. Macdonald V, Halliday GM. Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol Dis. 2002;10(3):378-86. (Pubitemid 35217589)
75. Macdonald V, Halliday GM, Trent RJ, McCusker EA. Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropathol Appl Neurobiol. 1997;23(6):492-95. (Pubitemid 28019851)
76. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry. 1998;55(3):215-24.
77. Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry. 2008;79(2): 130-5. (Pubitemid 351236541)
78. Bohanna I, Georgiou-Karistianis N, Egan GF. Connectivitybased segmentation of the striatum in Huntington's disease: vulnerability of motor pathways. Neurobiol Dis. 2011;42(3):475-81.
79. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology. 2005;65(5):745-7. (Pubitemid 41285856)
80. Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006;21(9):1317-25. (Pubitemid 44613279)
81. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791-801.
82. Gomez-Anson B, Alegret M, Munoz E, Monte GC, Alayrach E, Sanchez A, et al. Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance andCAGnumber. Parkinsonism Relat Disord. 2009;15(3):213-9.
83. Nopoulos P, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, et al. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis. 2010;40(3):544-54.
84. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004; 431(7010):805-10. (Pubitemid 39434070)
85. Reiner A, Del Mar N, Deng YP, Meade CA, Sun Z, Goldowitz D. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. The Journal of comparative neurology. 2007;505(6):603-29. (Pubitemid 350247129)
86. Davies SW, Turmaine M, Cozens BA, Raza AS, Mahal A, Mangiarini L, et al. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. Philos Trans R Soc Lond B Biol Sci. 1999;354(1386):981-9.
87. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537-48. (Pubitemid 27347243)
88. Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(12):5355-8. (Pubitemid 24174325)
89. Perutz MF. Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Current opinion in structural biology. 1996;6(6):848-58.
90. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 1995;14(5):1075-81.
91. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990-3. (Pubitemid 27449140)
92. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci. 1999;19(7):2522-34. (Pubitemid 29162401)
93. Maat-Schieman ML, Dorsman JC, Smoor MA, Siesling S, Van Duinen SG, Verschuuren JJ, et al. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. Journal of neuropathology and experimental neurology. 1999;58(2):129-37. (Pubitemid 29088937)
94. Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis. 1998;4(6):387-97. (Pubitemid 28201657)
95. Herndon ES, Hladik CL, Shang P, Burns DK, Raisanen J, White CL 3rd. Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. Journal of Neuropathology and Experimental Neurology. 2009;68(3):250-61.
96. van Roon-Mom WM, Hogg VM, Tippett LJ, Faull RL. Aggregate distribution in frontal and motor cortex in Huntington's disease brain. Neuroreport. 2006;17(6):667-70.
97. Lievens JC, Iche M, Laval M, Faivre-Sarrailh C, Birman S. AKT-sensitive or insensitive pathways of toxicity in glial cells and neurons in Drosophila models of Huntington's disease. Human molecular genetics. 2008;17(6): 882-94. (Pubitemid 351359704)
98. Weiss A, Roscic A, Paganetti P. Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's diseaselike neuronal dysfunction. Molecular neurodegeneration. 2009;4:11.
99. Kitamura A, Kubota H, Pack CG, Matsumoto G, Hirayama S, Takahashi Y, et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nature cell biology. 2006;8(10):1163-70. (Pubitemid 44473613)
100. Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, D'Ambola J, et al. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. The Journal of biological chemistry. 2009;284(16):10855-67.
101. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95(1):55-66.
102. White JK, AuerbachW, Duyao MP,Vonsattel JP, Gusella JF, Joyner AL, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAGexpansion. Nature genetics. 1997;17(4):404-10. (Pubitemid 27518388)
103. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS genetics. 2007;3(5):e82.
104. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO reports. 2004;5(10): 958-63. (Pubitemid 39534452)
105. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nature medicine. 2004;10Suppl: S10-7. (Pubitemid 38901862)
106. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, et al. Huntington aggregates may not predict neuronal death in Huntington's disease. Annals of neurology. 1999;46(6):842-9.
107. Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, et al. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci. 1999;19(4):1189-202. (Pubitemid 29088902)
108. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 2000;101(1):57-66.
109. Schiefer J, Landwehrmeyer GB, Luesse HG, Sprunken A, Puls C, Milkereit A, et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov Disord. 2002;17(4):748-57. (Pubitemid 41295019)
110. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Molecular therapy: the journal of the American Society of Gene Therapy. 2005;12(4):618-33. (Pubitemid 41350143)
111. Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochemical and biophysical research communications. 2006;343(1):190-7.
112. Reading SA, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, et al. Functional brain changes in presymptomatic Huntington's disease. Annals of neurology. 2004;55(6):879-83. (Pubitemid 38702585)
113. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci. 2001;21(23):9112-23. (Pubitemid 33096854)
114. Cammarata S, Caponnetto C, Tabaton M. Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: a pathological correlate of dementia? Neurosci Lett. 1993;156(1-2):96-8. (Pubitemid 23214733)
115. Sapp E, Penney J,Young A, Aronin N,Vonsattel JP, DiFiglia M. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. Journal of neuropathology and experimental neurology. 1999;58(2):165-73. (Pubitemid 29088940)
116. Sieradzan KA, Mann DM. The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Appl Neurobiol. 2001;27(1):1-21. (Pubitemid 32291184)
117. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Human molecular genetics. 2006;15(6):965-77. (Pubitemid 43338237)
118. Sotrel A,Williams RS, Kaufmann WE,Myers RH. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: a quantitative Golgi study. Neurology. 1993;43(10):2088-96. (Pubitemid 23318885)
119. Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS. The corticostriatal pathway in Huntington's disease. Progress in Neurobiology. 2007;81(5-6):253-71. (Pubitemid 46528639)
120. Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci. 2003;23(3):961-9. (Pubitemid 36206187)
121. Milnerwood AJ, Raymond LA. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol. 2007;585(Pt 3):817-31.
122. Andre VM, Cepeda C, Venegas A, Gomez Y, Levine MS. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J Neurophysiol. 2006;95(4): 2108-19.
123. Spampanato J, Gu X, Yang XW, Mody I. Progressive synaptic pathology of motor cortical neurons in aBACtransgenic mouse model of Huntington's disease. Neuroscience. 2008;157(3):606-20.
124. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002;33(6): 849-60. (Pubitemid 34246352)
125. Strand AD, Baquet ZC, Aragaki AK, Holmans PA, Yang L, Cleren C, et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci. 2007;27(43):11758-68. (Pubitemid 350006916)
126. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. 2004;24(17):4250-8. (Pubitemid 38620801)
127. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997; 389(6653):856-60. (Pubitemid 27462980)
128. Conner JM, Lauterborn JC,Yan Q, Gall CM,Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein andmRNAin the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci. 1997;17(7):2295-313. (Pubitemid 27137397)
129. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends in neurosciences. 2001;24(3):182-8. (Pubitemid 32166824)
130. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293(5529):493-8. (Pubitemid 32679077)
131. Ferrer I, Goutan E, Marin C, Rey MJ, Ribalta T. Brainderived neurotrophic factor in Huntington disease. Brain research. 2000;866(1-2):257-61. (Pubitemid 30313028)
132. Gambazzi L, Gokce O, Seredenina T, Katsyuba E, Runne H, Markram H, et al. Diminished activity-dependent brainderived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments. J Pharmacol Exp Ther. 2010;335(1):13-22.
133. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends in neurosciences. 2000;23(9):387-92.
134. Morton AJ, Faull RL, Edwardson JM. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res Bull. 2001;56(2):111-7. (Pubitemid 33026453)
135. Petersen A, Mani K, Brundin P. Recent advances on the pathogenesis of Huntington's disease. Exp Neurol. 1999;157(1):1-18. (Pubitemid 29226865)